Recent EORTC and MRC UK studies: implications for imaging ovarian cancer
نویسندگان
چکیده
For many years the primary management of newly diagnosed advanced ovarian cancer has been cytoreductive surgery followed by chemotherapy, and the mainstay of follow-up of treated women has been serial assay of serum CA-125. The findings of 2 recent research protocols have a significant effect on these aspects of management.
منابع مشابه
Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup (GCIG) and United States National Cancer
Objective—To review the current status of large phase academic clinical trials for women with ovarian cancer, address cross-cutting issues, and identify promising areas for future collaboration Materials/methods—In May, 2009, the Gynecologic Cancer Intergroup (GCIG), which represents 19 Cooperative Groups conducting trials for women with gynecologic cancer, and the United States National Cancer...
متن کاملCommentary: Mendelian randomization analysis identifies circulating vitamin D as a causal risk factor for ovarian cancer
doi: 10.1093/ije/dyw265 Commentary: Mendelian randomization analysis identifies circulating vitamin D as a causal risk factor for ovarian cancer Caroline J Bull*, James Yarmolinsky and Kaitlin H Wade School of Social and Community Medicine, University of Bristol, Bristol, UK, MRC/University of Bristol Integrative Epidemiology Unit, University of Bristol, Bristol, UK and IGFs and Metabolic Endoc...
متن کاملSurgical cytoreduction in ovarian cancer.
The majority of ovarian cancer patients present with advanced-stage disease, for which the goal of surgery is not only to document the extent of disease but also to perform surgical cytoreduction or tumor debulking. Cytoreductive surgery for ovarian cancer is generally performed at the time of diagnosis, when it is referred to as primary cytoreduction. It is also performed during primary chemot...
متن کاملESGO statement on the role of CA-125 measurement in follow-up of epithelial ovarian cancer.
T he recent publication of the OV05/EORTC 55955 study on the use of Cancer Antigen 125 (CA-125) in the followup of patients with ovarian cancer after primary treatment has challenged the assumed advantage of early detection of recurrent disease on the basis of a CA-125 rise. This study suggests that despite earlier initiation of second-line treatment, there is no survival benefit. Publication a...
متن کامل99mTc-Glucarate for assessment of paclitaxel therapy in human ovarian cancer in mice
Objectives: The monitoring of cancer treatment response to chemotherapy is considered an essential strategy for follow-up of patients. The aim of this study was to evaluate the use of 99mTc-glucarate as a radiotracer for in vivo quantification and visualization of necrotic area and therapeutic effect of paclitaxel in ovarian cancer xenografted nude mice. Materials and Methods: After implantatio...
متن کامل